262 related articles for article (PubMed ID: 21933972)
21. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
Garbe C; Orfanos CE
Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
[TBL] [Abstract][Full Text] [Related]
22. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study.
Feigelson HS; Powers JD; Kumar M; Carroll NM; Pathy A; Ritzwoller DP
Cancer Med; 2019 Aug; 8(9):4508-4516. PubMed ID: 31215776
[TBL] [Abstract][Full Text] [Related]
23. Poor adherence to beta-blockers is associated with increased long-term mortality even beyond the first year after an acute coronary syndrome event.
Allonen J; Nieminen MS; Sinisalo J
Ann Med; 2020; 52(3-4):74-84. PubMed ID: 32149544
[No Abstract] [Full Text] [Related]
24. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
25. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
[TBL] [Abstract][Full Text] [Related]
26. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study.
Hannibal CG; Jensen A; Sharif H; Kjaer SK
Cancer Causes Control; 2008 Sep; 19(7):759-65. PubMed ID: 18340541
[TBL] [Abstract][Full Text] [Related]
27. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study.
Nielsen PB; Larsen TB; Gorst-Rasmussen A; Skjøth F; Lip GY
Circ Heart Fail; 2016 Feb; 9(2):e002597. PubMed ID: 26823497
[TBL] [Abstract][Full Text] [Related]
28. Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
Borghi A; Corazza M; Virgili A; Lambertini AG; Caranci N; Pacelli B; Carcoforo P; Ferretti S
Melanoma Res; 2017 Dec; 27(6):619-624. PubMed ID: 28723726
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study.
Salles GF; Cardoso CR; Fonseca LL; Fiszman R; Muxfeldt ES
Am J Hypertens; 2013 Feb; 26(2):218-26. PubMed ID: 23382406
[TBL] [Abstract][Full Text] [Related]
30. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
[TBL] [Abstract][Full Text] [Related]
31. Age as a prognostic factor in the malignant melanoma population.
Austin PF; Cruse CW; Lyman G; Schroer K; Glass F; Reintgen DS
Ann Surg Oncol; 1994 Nov; 1(6):487-94. PubMed ID: 7850555
[TBL] [Abstract][Full Text] [Related]
32. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
Ishihara K; Saida T; Otsuka F; Yamazaki N;
Int J Clin Oncol; 2008 Feb; 13(1):33-41. PubMed ID: 18307017
[TBL] [Abstract][Full Text] [Related]
33. Rate-control treatment and mortality in atrial fibrillation.
Chao TF; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
Circulation; 2015 Oct; 132(17):1604-12. PubMed ID: 26384160
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993.
Koenig W; Löwel H; Lewis M; Hörmann A
Eur Heart J; 1996 Aug; 17(8):1199-206. PubMed ID: 8869861
[TBL] [Abstract][Full Text] [Related]
35. Dermatomyositis associated with malignant melanoma--a marker of poor prognosis?
Schiller M; Böhm M; Hensen P; Riemann H; Luger TA; Nashan D
J Am Acad Dermatol; 2006 Feb; 54(2):221-6. PubMed ID: 16443051
[TBL] [Abstract][Full Text] [Related]
36. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
[TBL] [Abstract][Full Text] [Related]
37. Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study.
Schubert-Fritschle G; Schlesinger-Raab A; Hein R; Stolz W; Volkenandt M; Hölzel D; Engel J
Int J Dermatol; 2013 Jun; 52(6):693-704. PubMed ID: 23432215
[TBL] [Abstract][Full Text] [Related]
38. The Role of β-Blockers in Melanoma.
De Giorgi V; Geppetti P; Lupi C; Benemei S
J Neuroimmune Pharmacol; 2020 Mar; 15(1):17-26. PubMed ID: 31482435
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
